Advertisement

Cardiovascular Drug Therapy in the Elderly

  • Adam Schneeweiss
  • Gotthard Schettler

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 72)

Table of contents

  1. Front Matter
    Pages i-x
  2. Agents Directly Enhancing Myocardial Contractility

    1. Front Matter
      Pages 1-1
    2. Adam Schneeweiss, Gotthard Schettler
      Pages 3-5
    3. Adam Schneeweiss, Gotthard Schettler
      Pages 6-28
    4. Adam Schneeweiss, Gotthard Schettler
      Pages 29-37
    5. Adam Schneeweiss, Gotthard Schettler
      Pages 38-44
    6. Adam Schneeweiss, Gotthard Schettler
      Pages 45-46
    7. Adam Schneeweiss, Gotthard Schettler
      Pages 47-50
    8. Adam Schneeweiss, Gotthard Schettler
      Pages 51-52
  3. Vasodilators

    1. Front Matter
      Pages 53-53
    2. Adam Schneeweiss, Gotthard Schettler
      Pages 55-55
    3. Adam Schneeweiss, Gotthard Schettler
      Pages 56-69
    4. Adam Schneeweiss, Gotthard Schettler
      Pages 70-77
    5. Adam Schneeweiss, Gotthard Schettler
      Pages 78-79
    6. Adam Schneeweiss, Gotthard Schettler
      Pages 80-103
    7. Adam Schneeweiss, Gotthard Schettler
      Pages 104-113
    8. Adam Schneeweiss, Gotthard Schettler
      Pages 114-135
    9. Adam Schneeweiss, Gotthard Schettler
      Pages 136-144
    10. Adam Schneeweiss, Gotthard Schettler
      Pages 145-155
    11. Adam Schneeweiss, Gotthard Schettler
      Pages 156-160
    12. Adam Schneeweiss, Gotthard Schettler
      Pages 161-174
    13. Adam Schneeweiss, Gotthard Schettler
      Pages 175-180
    14. Adam Schneeweiss, Gotthard Schettler
      Pages 181-190
    15. Adam Schneeweiss, Gotthard Schettler
      Pages 191-194
    16. Adam Schneeweiss, Gotthard Schettler
      Pages 195-199
  4. Antiarrhythmic Drugs

    1. Front Matter
      Pages 201-201
    2. Adam Schneeweiss, Gotthard Schettler
      Pages 203-204
    3. Adam Schneeweiss, Gotthard Schettler
      Pages 205-209
    4. Adam Schneeweiss, Gotthard Schettler
      Pages 210-216
    5. Adam Schneeweiss, Gotthard Schettler
      Pages 217-230
    6. Adam Schneeweiss, Gotthard Schettler
      Pages 231-237
    7. Adam Schneeweiss, Gotthard Schettler
      Pages 238-242
    8. Adam Schneeweiss, Gotthard Schettler
      Pages 243-250
    9. Adam Schneeweiss, Gotthard Schettler
      Pages 251-255
    10. Adam Schneeweiss, Gotthard Schettler
      Pages 256-260
    11. Adam Schneeweiss, Gotthard Schettler
      Pages 261-265
    12. Adam Schneeweiss, Gotthard Schettler
      Pages 266-285
    13. Adam Schneeweiss, Gotthard Schettler
      Pages 286-288
  5. Beta-Adrenoreceptor Blockers

    1. Front Matter
      Pages 289-289
    2. Adam Schneeweiss, Gotthard Schettler
      Pages 291-304
    3. Adam Schneeweiss, Gotthard Schettler
      Pages 305-327
    4. Adam Schneeweiss, Gotthard Schettler
      Pages 328-339
    5. Adam Schneeweiss, Gotthard Schettler
      Pages 340-350
    6. Adam Schneeweiss, Gotthard Schettler
      Pages 351-357
    7. Adam Schneeweiss, Gotthard Schettler
      Pages 358-362
    8. Adam Schneeweiss, Gotthard Schettler
      Pages 363-369
    9. Adam Schneeweiss, Gotthard Schettler
      Pages 370-374
  6. Centrally Acting Antihypertensive Agents

    1. Front Matter
      Pages 375-375
    2. Adam Schneeweiss, Gotthard Schettler
      Pages 377-377
    3. Adam Schneeweiss, Gotthard Schettler
      Pages 378-384

About this book

Introduction

Cardiovascular drug therapy has markedly progressed in the recent decades. Not only have new drugs been introduced to clinical practice, but new classes of drugs have been developed. While in 1960 the practicing cardiolo­ gist had a selection of about only ten drugs, in 1987 about 150 drugs are routinely used in cardiovascular diseases. Elderly patients, however, usually do not enjoy the full benefit of this progress. This might be due to lack of knowledge, a conservative approach, or the worldwide tendency not to try new drugs in the elderly. It is now clear that the majority of patients that will be treated in car­ diovascular clinics will be, in the near future, elderly patients. Even now, elderly patients form about one-third of the patients with cardiovascular diseases. These patients are approached, however, according to criteria devel­ oped for younger populations. This is despite the fact that elderly patients differ from younger ones in most aspects, including pathology, epidemiol­ ogy, pathophysiology, diagnostic approach, management, pharmacology, pharmacokinetics, rehabilitation, and supportive treatment. It is the purpose of this book to present to the clinician all drugs with which there is clinical experience in the elderly or which might be potentially useful for the elderly with cardiovascular diseases. The data are presented without the authors taking a position. This should allow the clinicians to make their own selection and individualize treatment, vii viii Preface based on a wide data base. Comparative data are presented only when specific comparative studies were performed.

Keywords

cardiovascular drugs heart disease physiology rehabilitation vascular disease

Authors and affiliations

  • Adam Schneeweiss
    • 1
  • Gotthard Schettler
    • 2
  1. 1.Geriatric Cardiology Research FoundationTel-AvivIsrael
  2. 2.Department of MedicineUniversity of HeidelbergGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4613-2063-0
  • Copyright Information Springer-Verlag US 1988
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4612-9225-8
  • Online ISBN 978-1-4613-2063-0
  • Series Print ISSN 0166-9842
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Internal Medicine & Dermatology